[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
March 26, 2014

Use of Placebo in a Trial of Thalidomide for Pediatric Crohn Disease—Reply

Author Affiliations
  • 1Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy
JAMA. 2014;311(12):1251-1252. doi:10.1001/jama.2014.1278

In Reply Although there are no specific guidelines for the use of a placebo in clinical trials of patients with Crohn disease, both the US Food and Drug Administration and the European Medicines Agency have released guidance documents on the choice of the control group, including a decision tree on how to identify the most appropriate one.1,2 Both agencies classify 5 types of control groups: placebo, active treatment, no treatment, dose-comparison, and external control.